Investigation of the infusion reaction development coursed by molecular target medicine prescription

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: University of the Ryukyus (2015); Nagoya City University (2013-2014)
• Principal Investigator: NAKAMURA Katsunori 琉球大学, 医学部附属病院, 教授 (20361363)
• Co-Investigator(Kenkyū-buntansha): KIMURA Kazunori 名古屋市立大学, 医学系研究科(研究院), 教授 (00423848) ; ANDO Yuichi 名古屋大学, 医学部附属病院, 教授 (10360083) ; MATSUNAGA Tamihide 名古屋市立大学, 医学系研究科(研究院), 教授 (40209581) ; Ohmori Shigeru 信州大学, 医学部附属病院, 教授 (70169069)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: Rituximab / infusion reaction / monoclonal antibody

Outline of Final Research Achievements

Rituximab also called RITUXAN can cause fever, a chill and the itch as adverse effects. This adverse effect sometimes could be severe, including fatal, infusion reaction (IR). Severe reactions typically occurred during the first infusion. In order to establish the method to avoid IR, risk factor of IR should be made clear. In this study, The patient who developed IR at Nagoya University hospital was 58.1% and at Nagoya City University hospital was 20.2％. The genomic DNA are picked out from blood of the patient who developed IR, and the responsible gene of a high-risk patient is being analyzed.

Free Research Field

薬理遺伝学